JP2006514945A - 循環器疾患造影用の標識マクロファージスカベンジャー受容体拮抗薬 - Google Patents

循環器疾患造影用の標識マクロファージスカベンジャー受容体拮抗薬 Download PDF

Info

Publication number
JP2006514945A
JP2006514945A JP2004558793A JP2004558793A JP2006514945A JP 2006514945 A JP2006514945 A JP 2006514945A JP 2004558793 A JP2004558793 A JP 2004558793A JP 2004558793 A JP2004558793 A JP 2004558793A JP 2006514945 A JP2006514945 A JP 2006514945A
Authority
JP
Japan
Prior art keywords
contrast agent
radioactive
agent according
metal ion
contrast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004558793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514945A5 (https=
Inventor
ウィルソン，イアン
ウィン，ダンカン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2006514945A publication Critical patent/JP2006514945A/ja
Publication of JP2006514945A5 publication Critical patent/JP2006514945A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004558793A 2002-12-06 2003-12-05 循環器疾患造影用の標識マクロファージスカベンジャー受容体拮抗薬 Pending JP2006514945A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228490.9A GB0228490D0 (en) 2002-12-06 2002-12-06 Novel imaging compounds
PCT/GB2003/005319 WO2004052357A1 (en) 2002-12-06 2003-12-05 Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases

Publications (2)

Publication Number Publication Date
JP2006514945A true JP2006514945A (ja) 2006-05-18
JP2006514945A5 JP2006514945A5 (https=) 2007-02-08

Family

ID=9949200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004558793A Pending JP2006514945A (ja) 2002-12-06 2003-12-05 循環器疾患造影用の標識マクロファージスカベンジャー受容体拮抗薬

Country Status (10)

Country Link
US (1) US20060239915A1 (https=)
EP (1) EP1567141A1 (https=)
JP (1) JP2006514945A (https=)
CN (1) CN1744890A (https=)
AU (1) AU2003292384B2 (https=)
CA (1) CA2508663A1 (https=)
GB (1) GB0228490D0 (https=)
NO (1) NO20052633L (https=)
RU (1) RU2005116983A (https=)
WO (1) WO2004052357A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503239A (ja) * 2007-11-07 2011-01-27 ジーイー・ヘルスケア・ベスローテン・ヴェンノーツハップ 放射性医薬品の安定化

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7886497B2 (en) 2003-12-02 2011-02-15 Valinge Innovation Ab Floorboard, system and method for forming a flooring, and a flooring formed thereof
GB0428020D0 (en) 2004-12-22 2005-01-26 Amersham Health As Stabilisation of radiopharmaceutical precursors
WO2006077901A1 (ja) * 2005-01-20 2006-07-27 Shionogi & Co., Ltd. Ctgf発現阻害剤
US11725395B2 (en) 2009-09-04 2023-08-15 Välinge Innovation AB Resilient floor
EP2473687B1 (en) 2009-09-04 2019-04-24 Välinge Innovation AB A method of assembling resilient floorboards which are provided with a mechanical locking system
PT3115161T (pt) 2011-08-29 2020-02-06 Ceraloc Innovation Ab Sistema de encaixe mecânico para painéis de pavimento
PT3358101T (pt) 2013-03-25 2020-01-21 Vaelinge Innovation Ab Tábuas de piso providas de um sistema de bloqueio mecânico e método para produzir um sistema de bloqueio deste tipo
EP3802514B1 (en) * 2018-06-01 2022-08-03 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078145A1 (en) * 1999-06-24 2000-12-28 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
WO2001098264A1 (en) * 2000-06-21 2001-12-27 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
WO2002067761A2 (en) * 2001-02-23 2002-09-06 Bristol-Myers Squibb Pharma Company Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078145A1 (en) * 1999-06-24 2000-12-28 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
WO2001098264A1 (en) * 2000-06-21 2001-12-27 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
WO2002067761A2 (en) * 2001-02-23 2002-09-06 Bristol-Myers Squibb Pharma Company Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503239A (ja) * 2007-11-07 2011-01-27 ジーイー・ヘルスケア・ベスローテン・ヴェンノーツハップ 放射性医薬品の安定化

Also Published As

Publication number Publication date
NO20052633D0 (no) 2005-06-01
EP1567141A1 (en) 2005-08-31
CA2508663A1 (en) 2004-06-24
RU2005116983A (ru) 2006-02-27
NO20052633L (no) 2005-07-06
US20060239915A1 (en) 2006-10-26
AU2003292384A1 (en) 2004-06-30
AU2003292384B2 (en) 2007-04-19
GB0228490D0 (en) 2003-01-08
CN1744890A (zh) 2006-03-08
WO2004052357A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
EP3755321B1 (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
Mastrostamatis et al. Tridentate ligands containing the SNS donor atom set as a novel backbone for the development of technetium brain-imaging agents
JP5043438B2 (ja) 阻害剤造影剤
JP6013735B2 (ja) 画像目的のためのヘキソースおよび金属配位結合化合物の結合体
KR20100121530A (ko) 관류 영상화를 포함하는 용도를 위한 조영제
US8506932B2 (en) Tetracyclic indole derivatives as in vivo imaging agents and having peripheralbenzodiazepine receptor affinity (PBR)
JP2013514326A (ja) 標識インテグリン結合剤
JP2009518372A (ja) 線維症用の新規造影剤
US8231858B2 (en) Diagnostic imaging agents with MMP inhibitory activity
JP2006514945A (ja) 循環器疾患造影用の標識マクロファージスカベンジャー受容体拮抗薬
JP2009518373A (ja) 線維症用の新規造影剤
JP2008514580A (ja) 酵素阻害剤造影剤
US20060120956A1 (en) Imaging agents comprising barbituric acid derivatives
WO2014122228A1 (en) Labelled compounds that bind to alpha-v-beta-3 integrin
Singh et al. A homodimeric bivalent radioligand derived from 1-(2-methoxyphenyl) piperazine with high affinity for in vivo 5-HT1A receptor imaging
Jackson et al. Rhenium diamino dithiol complexes. III. Lipophilic ligands for endotherapeutic radiopharmaceuticals
US20080279771A1 (en) Novel Imaging Agents for Cancer
Mastrostamatis et al. Institutes zyxwvutsrqponmlkjihgfed
EP2377852A1 (en) Labelled huprine derivatives and their use in medical imaging
KR20090096147A (ko) 폴피린 유도체, 그 제조방법, 및 그것을 포함하는 약제학적조성물

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100616

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100616

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100616

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100716

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100816

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101019

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110329